Close
  Indian J Med Microbiol
 

Figure 2: Course of disease on FCI (Red – Blasts; Green – Granulocytes; Blue – Lymphocytes). Row A: Aberrant expression of CD34, CD19, and dim CD56 at diagnosis; Row B: After the first cycle of arabinoside, daunorubicin, and etoposide. About 0.6% minimal residual disease with abnormal blasts expressing markers similar to the diagnostic phenotype. A small population of normal developing myeloid precursors (orange); Row C: After the second cycle of arabinoside, daunorubicin, and etoposide. Normal developing myeloid precursors and no minimal residual disease. Mast cells (black) showing bright CD117 expression with aberrant expression of CD25 and CD2. Internal control (T-lymphocytes) for CD2 is also seen

Figure 2: Course of disease on FCI (Red – Blasts; Green – Granulocytes; Blue – Lymphocytes). Row A: Aberrant expression of CD34, CD19, and dim CD56 at diagnosis; Row B: After the first cycle of arabinoside, daunorubicin, and etoposide. About 0.6% minimal residual disease with abnormal blasts expressing markers similar to the diagnostic phenotype. A small population of normal developing myeloid precursors (orange); Row C: After the second cycle of arabinoside, daunorubicin, and etoposide. Normal developing myeloid precursors and no minimal residual disease. Mast cells (black) showing bright CD117 expression with aberrant expression of CD25 and CD2. Internal control (T-lymphocytes) for CD2 is also seen